<DOC>
	<DOCNO>NCT01255371</DOCNO>
	<brief_summary>In well recognize context HIV infection chronicity , crucial identify evaluate effective , well tolerate affordable second line regimen resource limited country patient often change treatment long period viral replication first line regimen . This multicentre international , randomize , non-blinded phase III trial aim demonstrate non-inferiority generic lamivudine-tenofovir-atazanavir/ritonavir regimen ( daily intake ) compare standard emtricitabine-tenofovir-lopinavir/ritonavir ( twice daily intake ) regimen second line HIV-1 treatment . stratify viral load level ( 1000 5000 copies/mL versus &gt; 5000 copies/mL ) inclusion , trial also allow evaluate optimum moment institute second-line treatment .</brief_summary>
	<brief_title>A Multicentre Trial Second-line Antiretroviral Treatment Strategies African Adults Using Atazanavir Lopinavir/Ritonavir</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>age 18 patient document HIV1 infection first line treatment failure : firstline antiretroviral treatment combination include nonnucleoside reverse transcriptase inhibitor two nucleoside reverse transcriptase inhibitor two measurement plasma HIV RNA level &gt; 1000 copies/mL least 6 month uninterrupted treatment without major modification satisfactory compliance ( &gt; 80 % ) 1st line antiretroviral treatment sign informed consent agreement contraception woman childbearing age HIV2 infection HIV1/HIV2 coinfection uncontrolled , ongoing opportunistic infection severe progressive disease include active TB first line antiretroviral treatment protease inhibitor tenofovir ongoing treatment rifampicin severe hepatic insufficiency ( PT &lt; 50 % ) ALT &lt; 3 time upper limit normal creatinine clearance calculate Cockcroft 's formula &lt; 50 mL/min Hb &lt; =8 g/dL ; platelet &lt; 50,000 cells/mm3 ; neutrophil &lt; 500 cells/mm3 pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>Second line antiretroviral treatment</keyword>
	<keyword>Sub saharian Africa</keyword>
	<keyword>Generic</keyword>
</DOC>